How Kidney Disease Affects Tirzepatide Treatment for Heart Failure
Chronic kidney disease worsened heart failure severity but did not diminish tirzepatide benefits, though kidney function changes were hard to assess due to body composition shifts.
Quick Facts
What This Study Found
CKD doubled heart failure event rates, but tirzepatide benefits were consistent across kidney function levels. Creatinine-based and cystatin C-based eGFR gave discordant results.
Key Numbers
Of 1,145 participants: 8.8% under 55, 23.3% aged 55-64, 42.4% aged 65-74, 25.5% aged 75+. KCCQ-CSS interaction P = 0.80. Body weight interaction P not significant. Treatment: 52 weeks.
How They Did This
Pre-specified analysis of the SUMMIT double-blind RCT with 731 patients enriched for CKD.
Why This Research Matters
Many HFpEF patients have CKD, and understanding drug-kidney interactions is essential for safe prescribing.
The Bigger Picture
Weight-loss therapies create measurement challenges for kidney function tracking, requiring clinicians to use cystatin C-based estimates.
What This Study Doesn't Tell Us
Sub-analysis of SUMMIT; not powered for CKD subgroup outcomes. Short-term renal function data.
Questions This Raises
- ?Should cystatin C-based eGFR become standard for patients on GLP-1/GIP drugs?
- ?Does tirzepatide have direct renoprotective effects?
Trust & Context
- Key Stat:
- 2x Higher heart failure event rate in patients with chronic kidney disease
- Evidence Grade:
- Pre-specified sub-analysis of a high-quality RCT. Moderate evidence for CKD subgroup findings.
- Study Age:
- Published in 2025 from the SUMMIT trial.
- Original Title:
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
- Published In:
- European journal of heart failure, 27(11), 2537-2543 (2025)
- Authors:
- Pandey, Ambarish(6), Moroney, Michael, Verma, Subodh(15), Borlaug, Barry A, Butler, Javed, Davies, Melanie J, Kitzman, Dalane W, Shah, Sanjiv J, Petrie, Mark C, Rönnbäck, Cecilia, Domdey, Anne, Rasmussen, Søren, Chinnakondepalli, Khaja M, Patel, Shachi, Kosiborod, Mikhail N
- Database ID:
- RPEP-12934
Evidence Hierarchy
Frequently Asked Questions
Can patients with kidney disease take tirzepatide for heart failure?
Yes. This analysis found tirzepatide benefits were consistent regardless of kidney function, though monitoring with cystatin C-based tests is recommended.
Why are kidney tests unreliable during tirzepatide treatment?
Weight loss changes muscle mass, which affects creatinine-based kidney tests. Cystatin C-based measurements are not affected by body composition changes.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12934APA
Pandey, Ambarish; Moroney, Michael; Verma, Subodh; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Kitzman, Dalane W; Shah, Sanjiv J; Petrie, Mark C; Rönnbäck, Cecilia; Domdey, Anne; Rasmussen, Søren; Chinnakondepalli, Khaja M; Patel, Shachi; Kosiborod, Mikhail N. (2025). Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.. European journal of heart failure, 27(11), 2537-2543. https://doi.org/10.1002/ejhf.70049
MLA
Pandey, Ambarish, et al. "Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.." European journal of heart failure, 2025. https://doi.org/10.1002/ejhf.70049
RethinkPeptides
RethinkPeptides Research Database. "Effects of semaglutide in obesity-related heart failure with..." RPEP-12934. Retrieved from https://rethinkpeptides.com/research/pandey-2025-effects-of-semaglutide-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.